Skip to content

A study to evaluate the effect of food ingredient in healthy adult on the blood glucose level -Open label,single intake comparative method

A study to evaluate the effect of food ingredient in healthy adult on the blood glucose level -Open label,single intake comparative method - A study to evaluate the effect of food ingredient in healthy adult on the blood glucose level

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000053931
Enrollment
15
Registered
2024-03-22
Start date
2024-03-21
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy adult

Interventions

Placebo food (a single time intake)&gt
Test foods (a single time intake)

Sponsors

Kewpie Corporation
Lead Sponsor
CXwellness Company Limited
Collaborator

Eligibility

Sex/Gender
Male

Inclusion criteria

Inclusion criteria: (1) Japanese males between 20 and 75 years of age. (2) Subjects who voluntarily wish to participate in the clinical trial and provide written consent. (3) Subjects who able to maintain a consistent daily lifestyle during the study period.

Exclusion criteria

Exclusion criteria: (1) Subjects with serious diseases (diabetes, heart disease, cancer, etc.) or mental illness. (2) Subjects with a history of serious diseases (diabetes, heart disease, liver disease, renal disease, cancer, etc.) in the past. (3) Subjects who have donated more than 200mL of blood in the past month or 400mL within the past 3 months. (4) Subjects who have experienced illness or deterioration of physical condition due to blood collection in the past. (5) Subjects who have symptoms of severe anemia. (6) Subjects who are unable to maintain their daily lifestyle due to significant changes in diet and physical activity. (7) Subjects with possible food or drug allergies to the test foods. (8) Subjects who consume food for specified health use, health food, etc. on a daily basis. (9) Subjects who are otherwise ineligible for participation in this study by the investigater.

Design outcomes

Primary

MeasureTime frame
Blood glucose level,Insulin level

Secondary

MeasureTime frame
Glucose dependent insulinotropic polypeptide level,and Glucagon Like Peptide-1 level

Countries

Japan

Contacts

Public ContactTatsuo Uetake

CXwellness Company Limited Representative Director

uetake@cx-wellness.com03-6915-5507

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026